Spots Global Cancer Trial Database for Combined Immunotherapies in Metastatic ER+ Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Combined Immunotherapies in Metastatic ER+ Breast Cancer
Official Title: CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer
Study ID: NCT04563507
Conditions
Study Description
Brief Summary: Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for metastatic HR+ Breast cancer(BC) (letrozole+palbociclib) are randomly assigned to also receive Stereotactic Body Radiation Therapy(SBRT) to each metastatic lesion.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Weill Cornell Medicine, New York, New York, United States
Brooklyn Methodist Hospital - NewYork Presbyterian, New York, New York, United States
New York Presbyterian Hospital - Queens, New York, New York, United States
Contact Details
Name: Silvia Formenti, M.D.
Affiliation: Weill Medical College of Cornell University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
